Wegovy, Mounjaro and IVF require coordinated planning rather than a simple yes-or-no answer. GLP-1 medicines are not recommended during pregnancy, and drug-specific washout periods apply before trying to conceive. Egg-retrieval anesthesia, contraception and management of the underlying condition also need discussion.
Weight management and fertility treatment sometimes overlap, creating questions about timing and medicines. The answer depends on the treatment stage and the specific drug, not simply whether IVF is planned.
Separate metabolic treatment from fertility treatment
Semaglutide and tirzepatide may be prescribed for approved indications. They should not be represented as proven IVF-success medicines.
Limited human reproductive evidence cannot establish either improved egg quality or absence of risk. Better glucose or weight outcomes are not proof of improved implantation or live birth.
Pregnancy and procedures both matter
These medicines are not recommended in pregnancy. Before egg retrieval, the anesthesia team also needs to know about use because delayed gastric emptying can affect procedural planning.
Plan the washout
UK MHRA guidance advises stopping semaglutide at least two months and tirzepatide at least one month before trying to conceive. Discuss the applicable product guidance and an individualized plan with the prescribing and fertility teams.
- Indication and timing: A prescriber should determine whether metabolic medication is appropriate and how it fits the fertility plan.
- The Retrieval Phase: If the patient is already on these drugs, some clinicians may advise a temporary cessation prior to egg retrieval, particularly because these drugs delay gastric emptying. This can pose an aspiration risk during the conscious sedation used for egg collection.
- Before conception: Follow drug-specific washout advice; do not infer one interval for the entire GLP-1 class.
If pregnancy is possible, contraception needs attention. With tirzepatide, UK guidance advises additional barrier contraception for four weeks after starting and after each dose increase, or a suitable non-oral method.
- Wegovy: Discontinue at least 2 months before planned conception.
- Mounjaro: Discontinue at least 1 month before planned conception.
Stopping a medicine also requires a plan for the condition being treated, especially diabetes. Do not change treatment solely from a general article.
Plan the timing together
Metabolic treatment, reproductive plans, medication washout and procedural safety need a coordinated plan tailored to the patient and the drug.
A coordinated plan, not a safety guarantee
A washout period is a precaution, not proof that every outcome will be safe. Timing should be agreed across fertility, prescribing and anesthesia care.
Disclaimer: This report is for informational purposes. The use of weight-loss medications in the context of fertility treatment must be managed under the strict supervision of a reproductive endocrinologist.
Check the applicable product advice
Pregnancy precautions and washout periods are drug-specific. The UK MHRA also explains contraceptive precautions with tirzepatide. UK MHRA: GLP-1 medicines and pregnancy planning.
Related reading
GLP-1 Drugs and Male Fertility: Could Weight-Loss Treatment Help Sperm?